Rallybio

Rallybio is a clinical-stage biotechnology company, listed on NASDAQ as RLYB, focused on developing life-transforming therapies for severe and rare diseases. With a strong pipeline targeting maternal fetal health, complement dysregulation, hematology, and metabolic disorders, they have two clinical stage programs: RLYB212, an anti-HPA-1a antibody for preventing Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), and RLYB116, a complement component 5 (C5) inhibitor that has the potential to address several diseases of complement dysregulation. The company, founded in 2018, is based in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. In April 10, 2024, Rallybio secured a $6.60M Post-IPO Equity investment from Johnson & Johnson Innovation – JJDC. The company emphasizes the importance of fostering the best people, partners, and scientific advancements to achieve their mission. Rallybio's dedication to overcoming challenging scientific barriers is evident through its diverse pipeline and strategic partnerships.